arrow
C

Catherine Shannon

mater cancer care centre
H指数:24
被引数:2,254

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial

奥拉帕利、度伐利尤单抗和环磷酰胺,以及铂敏感卵巢癌的预后血液特征:随机Ⅱ期SOLACE2试验

2025-11-050
OA
Effect of a Standardized Ginger Root Powder Regimen on Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Double-Blind, Placebo-Controlled Randomized Trial

标准化姜根粉方案对化疗引起的恶心和呕吐的影响: 一项多中心、双盲、安慰剂对照随机试验

2024-03-0117
OAAI
ACE-Breast-03: Efficacy and safety of ARX788 in patients with HER2+metastatic breast cancer previously treated with T-DM1
2023-03-011
PRE
VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, and Biomarker Results

VERONICA: 氟维司特和维尼托克治疗ER阳性转移性乳腺癌Post-CDK4/6抑制剂的随机II期研究-疗效、安全性和生物标志物结果

2022-05-1843
OAAI
A global, phase 2 study of ARX788 in patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens
2022-02-150
PRE
Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer
2016-02-0437
OA
Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance
2015-04-2042
OAAI